Role of atherogenic indices in predicting infertility in polycystic ovary syndrome
- PMID: 40802395
- PMCID: PMC12341413
- DOI: 10.1590/1806-9282.20241460
Role of atherogenic indices in predicting infertility in polycystic ovary syndrome
Abstract
Objective: The aim of the study was to assess the predictive value of the triglyceride-glucose index and atherogenic indices for infertility in women with polycystic ovary syndrome.
Methods: This prospective, single-center, non-randomized observational study was conducted on 279 women diagnosed with polycystic ovary syndrome from May to December 2023. Women with polycystic ovary syndrome were grouped into two groups: those with infertility and those without infertility. Demographic, hormonal, and clinical parameters were studied. The statistical study employed IBM SPSS (Statistical Package for the Social Sciences) Statistics 22 to analyze the distribution of variables, assessing normality and comparing categorical and continuous data. Descriptive statistics were computed, with categorical and continuous data compared using appropriate tests (chi-square, Student's t-test, and Mann-Whitney U). Multivariable logistic regression identified independent predictors of infertility, with a significance level set at 0.05.
Results: Infertile women with polycystic ovary syndrome had significantly higher plasma levels of dehydroepiandrosterone sulfate (p=0.001), testosterone (p=0.005), insulin (p=0.041), Homeostasis Model Assessment of Insulin Resistance (p=0.029), prolactin (p=0.018), triglycerides (p<0.001), triglyceride/high-density lipoprotein (p=0.001), atherogenic index of plasma (p=0.011), triglyceride-glucose index (p=0.001), and lipoprotein combine index (p=0.007) compared to the fertile women with polycystic ovary syndrome. Correlation analysis showed that the triglyceride-glucose index correlated with the Homeostasis Model Assessment of Insulin Resistance (r=0.402, p<0.001) and total testosterone (r=0.191, p=0.001). Multivariable analysis identified age (OR 1.189, 95%CI 1.122-1.263, p<0.001), prolactin (OR 1.040, 95%CI 1.004-1.077, p=0.029), and triglyceride-glucose index (OR 2.473, 95%CI 1.404-4.177, p<0.001) as independent predictors of infertility.
Conclusion: This study suggests a more atherogenic lipid profile in infertile women with polycystic ovary syndrome, suggesting a significant link between dyslipidemia and infertility. The triglyceride-glucose index proves to be a reliable, non-invasive marker of insulin resistance and may aid in identifying women at higher risk for infertility, facilitating earlier, targeted interventions.
Conflict of interest statement
Similar articles
-
Elevated Triglyceride-Glucose Index Is Associated With Insulin Resistance, Metabolic Syndrome Components, Nonalcoholic Fatty Liver Disease, and Adverse Pregnancy Outcomes in Chinese Women With Polycystic Ovary Syndrome.Clin Endocrinol (Oxf). 2025 Sep;103(3):317-326. doi: 10.1111/cen.15252. Epub 2025 Apr 29. Clin Endocrinol (Oxf). 2025. PMID: 40298068 Free PMC article.
-
Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review.Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:38-62. doi: 10.1016/j.ejogrb.2022.01.025. Epub 2022 Feb 1. Eur J Obstet Gynecol Reprod Biol. 2022. PMID: 35149444
-
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article.
-
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4. Cochrane Database Syst Rev. 2022. PMID: 36165742 Free PMC article.
-
In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.Cochrane Database Syst Rev. 2025 Feb 6;2(2):CD006606. doi: 10.1002/14651858.CD006606.pub5. Cochrane Database Syst Rev. 2025. PMID: 39912435
References
-
- Medeiros SF, Winck Yamamoto Medeiros AL, Souto Medeiros MA, Silva Carvalho AB, Yamamoto MW, Soares JM, et al. Anthropometric, metabolic, and endocrine parameters as predictors of estimated average glucose and other biomarkers of dysglycemia in women with different phenotypes of polycystic ovary syndrome. Horm Metab Res. 2024;56(6):445–454. doi: 10.1055/a-2207-0739. - DOI - PubMed
-
- Medeiros SF, Junior JMS, Medeiros MAS, Yamamoto AKLW, Medeiros CLW, Silva Carvalho AB, et al. Combined oral contraceptive use and obesity in women with polycystic ovary syndrome. A meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2024;310(4):2223–2233. doi: 10.1007/s00404-024-07637-5. - DOI - PubMed
-
- Soares-Jr JM, Hayashida SAY, Marcondes JAM, Maciel GAR, Barcellos CRG, Maffazioli GN, et al. Influence of phenotypes on the metabolic syndrome of women with polycystic ovary syndrome over a six-year follow-up in Brazil. Biomedicines. 2023;11(12):3262–3262. doi: 10.3390/biomedicines11123262. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources